Serum-derived Bovine Immunoglobulin Effect on Mucositis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04239261|
Recruitment Status : Terminated (Recruitment slower than anticipated)
First Posted : January 27, 2020
Last Update Posted : January 26, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Mucositis||Dietary Supplement: SBI Dietary Supplement: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Randomized, Placebo-Controlled, Pilot Study of Serum-Derived Bovine Immunoglobulin/Protein Isolate to Manage Mucositis in Patients Undergoing Treatment for Head, Neck, or Lung Cancer|
|Actual Study Start Date :||January 17, 2020|
|Actual Primary Completion Date :||January 24, 2023|
|Actual Study Completion Date :||January 24, 2023|
Active Comparator: Nutritional therapy
Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams once daily
Dietary Supplement: SBI
Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
Placebo Comparator: Placebo
Hydrolyzed gelatin 10.0 grams once daily
Dietary Supplement: Placebo
Hydrolyzed gelatin 10.0 g once daily
- Development of Oral Mucositis during ChemoRadiation Treatment [ Time Frame: Baseline and Up to approximately 90 days after randomization ]CTCAE version 5 will be used to determine adverse event grade of mucositis, if applicable
- Development of Dysphagia during ChemoRadiation Treatment [ Time Frame: Baseline and Up to approximately 90 days after randomization ]CTCAE version 5 will be used to determine advent grade of dysphagia, if applicable
- Change in Bowel Movements [ Time Frame: Baseline and Up to approximately 90 days after randomization ]Stool Diary Card will be completed by patient to document consistency, ease and completeness
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Informed consent obtained and signed
- Male or female at least 18 years of age
- Diagnosed with head, neck, or lung cancer and scheduled to undergo combined chemo-radiation therapy
- Diagnosed with head, neck, or lung cancer with disease stage within the criteria described in 4.0 Staging Criteria
- Not experiencing diarrhea during the 5 days preceding enrollment, as defined by having less than two unformed bowel movements per day or loose (mushy) or watery stools in the 5 days preceding enrollment.
- Not currently taking anti-diarrheal medications (prescription or over the counter).
- Agrees and is able to take the investigational products or placebo starting from the day of enrollment (approximately 7-14 days prior to beginning chemo-radiation therapy) through 6-7 weeks of chemo-radiation therapy (for a total of 8-9 weeks).
- History of uncontrolled diarrhea during screening.
- History of Irritable Bowel Syndrome with Diarrhea with a normal pattern of more than three bowel movements in a 24 hour period.
- History of inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis.
- History of active infectious diarrhea and receiving therapy within 10 days of the first dose of study drug or placebo.
- Known allergy or intolerance to beef or soy or any ingredient used in the product
- History of concurrent intensive chemotherapy within 10 days of the first scheduled dose of study drug or placebo.
- Gastrointestinal surgery or bowel resection that could affect study product absorption (this does not include cholecystectomy or appendectomy).
- Unable to comply with the protocol requirements.
- Any condition that in the opinion of the Investigator might interfere with the study objective.
- Women who are pregnant or breastfeeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04239261
|United States, Iowa|
|MercyOne Des Moines Medical Center|
|Des Moines, Iowa, United States, 50314|
|Principal Investigator:||Richard Deming, MD||MercyOne Des Moines Medical Center|
|Responsible Party:||Richard Deming, MD, Principal Investigator, MercyOne Des Moines Medical Center|
|Other Study ID Numbers:||
|First Posted:||January 27, 2020 Key Record Dates|
|Last Update Posted:||January 26, 2023|
|Last Verified:||January 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||Yes|
Digestive System Diseases